FDA Approves Datroway for HER2-Negative Metastatic Breast Cancer
On January 17, the Food and Drug Administration (FDA) approved Datroway (datopotamab deruxtecan, or Dato-DXd) for people with previously treated inoperable or metastatic hormone receptor-positive/HER2-negative positive breast cancer. The new targeted …